Amphastar Pharmaceuticals, Inc.
AMPH offers a discounted earnings recovery with real product-launch optionality, but the investment case depends on containing an IMS issue that touches roughly one-third of sales.
The market is valuing AMPH as a damaged generic manufacturer, not as a company with an earnings recovery path and several product-level offsets. That skepticism is understandable. The IMS facility issue affects roughly one-third of sales, carries a stated $2M-$3M quarterly expense burden, and has introduced batch-release delays. The quality issue matters more than a one-quarter earnings beat because it determines whether customers, regulators, and investors can trust the manufacturing platform that supports the portfolio.
The reason to own the shares is that the downside case is already reflected more heavily than the recovery case. The company trades at 1.52x TTM sales and 1.45x book value, while its current ratio is 2.40. A successful remediation outcome need not produce flawless execution to create value. It only needs management to preserve supply continuity, hold its FY26 growth range, and prevent the recent margin damage from becoming structural. Ipratropium is the tangible proof point: the April launch delivered $8.4M in Q2 sales. Insulin aspart provides a second, later opportunity, with commercialization targeted for 2027 subject to regulatory approval.
The harder question is earnings quality. BAQSIMI demand is healthy at the prescription level, but price realization is deteriorating through rebates and 340B discounts. Glucagon is declining much faster than the rest of the company can tolerate if no new launches replace it. The $100M Lilly payment due after BAQSIMI crossed its annual-sales threshold also reduces financial flexibility at an inconvenient point in the remediation cycle. This is why the stock merits a buy rating, but not a high-conviction one.
A favorable outcome requires three things: IMS costs remain within guidance, launch revenue grows beyond the initial ipratropium contribution, and the company converts gross-margin improvement from higher-margin products into durable operating margin. If any one fails, the low TTM multiple may prove deserved. If all three hold, the current price does not reflect AMPH's forward earnings capacity.
New launches scale, IMS costs fade without supply disruption, and investors assign a stronger earnings multiple to a recovering portfolio.
FY26 growth guidance holds, ipratropium and BAQSIMI demand offset legacy erosion, and remediation costs remain limited to the guided range.
IMS delays broaden beyond one-third of sales, legacy-product declines persist, and LTM-level margin pressure prevents an earnings recovery.
Quant call (BUY) diverges from analyst consensus (Sell: 0 buy / 3 hold / 1 sell) — resolve explicitly.
In the short run, the market is a voting machine, but in the long run, it is a weighing machine.
FY26 guidance calls for mid-single-digit to high-single-digit sales growth, but management has not supplied an earnings guide or a forward EPS estimate from which to calculate a reliable forward P/E; the relevant valuation anchor is therefore 14.64x TTM P/E rather than a modeled forward multiple. The moat today is FDA-regulated manufacturing know-how, inhalation and injectable formulation capability, and branded franchise distribution, but its durability over three to five years is weakened by generic price competition and the IMS quality burden. AI is not a material source of product differentiation for AMPH, though it can improve quality analytics and manufacturing review cycles; it cannot substitute for FDA compliance or create exclusivity. The 2027 insulin aspart launch and respiratory launches expand the addressable portfolio, while reimbursement pressure, 340B discounts, and generic substitution limit how much of that growth becomes margin.
- FY26 sales guidance remains mid-single digit to high-single digit growth, supported by new launches including $8.4M of Q2 ipratropium revenue.
- Q2 adjusted EPS of $0.91 beat the $0.62 Street estimate by 46.8%, while EBITDA margin reached 33.5%.
- The $26.33 share price values AMPH at 14.64x TTM P/E, versus 40.0x for the peer set and a $38.52 quant base value.
- Q2 revenue rose 5% YoY to $183.9M, and management did not reduce its FY26 corporate sales-growth outlook despite the IMS work.
- Ipratropium generated $8.4M in its first full quarter after the April launch, showing that the respiratory pipeline can replace pressure on older products.
- BAQSIMI prescriptions increased 17% YoY, indicating underlying franchise demand even though Q2 reported BAQSIMI sales declined 3% YoY on net-price pressure.
- AMPH produced $0.2B of LTM FCF against a $1.1B market capitalization and repurchased about $45M of stock in Q2.
- IMS represents roughly one-third of sales and requires $2M-$3M of expense per quarter for the next several quarters, with added quality reviews already causing batch-release delays.
- LTM operating margin was 15.7% through June 30, 2026, down from 26.7% in FY2025, showing that the recovery seen in Q2 is not yet reflected in trailing profitability.
- Glucagon sales declined 42% YoY in Q2 amid intensifying competition, while BAQSIMI net sales declined 3% YoY despite prescription growth.
- Leverage is meaningful at 3.60x LTM debt/EBITDA and 0.90 debt/equity as of June 30, 2026, ahead of a $100M Lilly payment triggered by BAQSIMI crossing its $175M sales threshold.
| Metric | Value | Context |
|---|---|---|
| Share price | $26.33 | Current price, 10.8% below the 52-week high of $29.52 |
| Market capitalization | $1.1B | Current equity value |
| Revenue | $0.7B FY2025 | 2.2% YoY growth |
| EPS | $2.10 FY2025 | 14.8% YoY decline |
| Operating margin | 15.7% LTM to 2026-06-30 | Below 26.7% FY2025 |
| Net margin | 10.8% LTM to 2026-06-30 | Below 19.4% FY2025 |
| P/E | 14.64x TTM | Versus peer average 40.0x |
| P/S | 1.52x TTM | Versus peer average 1.7x |
| Leverage | 3.60x debt/EBITDA LTM to 2026-06-30 | Total debt was $0.7B as of 2026-06-30 |
| Free cash flow | $0.2B LTM to 2026-06-30 | Cash-flow quality score is 100/100 |
| FY26 sales guidance | Mid-single digit to high-single digit growth | Reaffirmed on the 2026 Q2 call |
| Price momentum | +30.09% over 3 months | Price is 18.3% above its 200-day average |
The IMS remediation issue could turn from a $2M-$3M quarterly cost into a broader supply or regulatory disruption across roughly one-third of sales, impairing both FY26 growth and margin recovery.
November 5, 2026 earnings, specifically confirmation of FY26 sales growth guidance, IMS batch-release progress, and whether Q2's 33.5% EBITDA margin can be sustained.
Institutional ownership is concentrated, with the top three institutions holding 55.4%, while insiders hold 9.0%. Short interest is elevated at 13.85% of shares, or 4.33M shares, with 9.2 days to cover on a 31M float, creating upside pressure if execution improves but also signaling material skepticism. Options gamma is reported as positive, but no usable zero-gamma or strike-wall levels were supplied, so it should not drive the investment decision.
The facility remains operational, but added quality reviews are causing modest batch-release delays and $2M-$3M quarterly remediation expense.
Launched in April 2026 and led Q2 growth, providing early evidence that respiratory launches can add revenue.
Prescriptions grew 17% YoY, but sales fell 3% YoY as rebates and 340B discounts reduced net price; annual sales exceeded $175M.
Sales fell 42% YoY in Q2 as ready-to-use competitive products intensified pressure.
The prior European BAQSIMI transition had supply disruptions across 14 countries, but current geographic revenue is unavailable.
Q2 profitability rebounded and FY26 sales growth guidance held, but IMS remediation costs and legacy-product pressure remain key offsets.
Management's record is mixed rather than serially strong: the last eight reported quarters contain four beats and four misses, including a 46.8% Q2 2026 beat after misses of 40.0% and 19.2% in the prior two quarters. Since the 2024 Q3 call, EBITDA margin improved from 21.9% to 33.5% in Q2 2026, but Q2 gross margin was only 51% versus 53% two years earlier, and LTM operating margin is 15.7%. The 2024 promise of BAQSIMI peak sales of $250M-$275M has not been confirmed, while current sales cleared the $175M payment threshold but declined 3% YoY in Q2. Insulin aspart was discussed as a Q4 2024 BLA refiling, yet commercial launch is now expected in 2027 subject to approval; this is progress, not proof that the original timeline translated into revenue. Management deserves credit for retaining FY26 growth guidance through remediation, but the uneven beat record and unresolved facility work keep credibility below high-conviction levels.
Importantly, even with this revised outlook, we maintain our overall corporate sales guidance of mid-single digit to high single-digit sales growth, reflecting the strength of our broader portfolio.
Due to remediation efforts at our IMS facility, we expect expenses there will increase by $2 million to $3 million per quarter for the next several quarters.
Ipratropium Bromide Inhalation, which we launched in April, led to growth with strong sales of $8.4 million.
On a going forward basis, I would expect to see the coming quarter similar to this quarter, because remember, we'll have higher BAQSIMI sales next quarter, those higher sales should offset some of the costs that we're expecting at IMS.
What I'll say about that product is we're on schedule for that to have our commercial launch of the product next year in 2027.
AMPH's protection comes from difficult-to-replicate sterile, inhalation, and complex injectable manufacturing, plus FDA approvals and commercial relationships around products such as BAQSIMI and Primatene Mist. That moat is meaningful in technical products, but not absolute: glucagon's 42% YoY decline illustrates that product competition can overwhelm formulation advantages. Over three to five years, the moat improves only if the company converts its manufacturing base into reliable launches while restoring quality-system credibility at IMS.
The company generated $0.2B of LTM FCF and used approximately $45M for Q2 repurchases, continuing the board's earlier $50M authorization. That capital return is attractive at a 14.64x TTM P/E, but leverage of 3.60x LTM debt/EBITDA argues for prioritizing debt capacity, the pending $100M Lilly payment, and remediation needs before aggressive buybacks. Supplied deep-dive data lists zero capex, dividends, and buybacks, so confirmed Q2 repurchases are the more reliable indicator of current deployment.
AMPH rates a BUY with Medium conviction for the next 6-12 months. The valuation discounts real problems, but it also discounts the maintained FY26 growth outlook, new respiratory revenue, and a possible 2027 insulin aspart contribution. The November 5 earnings release is the immediate test of whether Q2 was a recovery or an isolated quarter. A downgrade would follow evidence that IMS disruption spreads beyond its current roughly one-third sales exposure, remediation costs exceed the guided range, or management cuts the FY26 growth outlook.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. Rated BUY, Medium conviction. AMPH is priced at 14.64x TTM P/E, well below the 40.0x peer average, despite management retaining FY26 sales-growth guidance and posting a Q2 adjusted EPS beat of 46.8%. The setup is not clean: LTM operating margin has fallen to 15.7%, IMS remediation is a direct earnings drag, and the stock has already risen 30.09% over three months.
Investment Thesis
The market is valuing AMPH as a damaged generic manufacturer, not as a company with an earnings recovery path and several product-level offsets. That skepticism is understandable. The IMS facility issue affects roughly one-third of sales, carries a stated $2M-$3M quarterly expense burden, and has introduced batch-release delays. The quality issue matters more than a one-quarter earnings beat because it determines whether customers, regulators, and investors can trust the manufacturing platform that supports the portfolio.
The reason to own the shares is that the downside case is already reflected more heavily than the recovery case. The company trades at 1.52x TTM sales and 1.45x book value, while its current ratio is 2.40. A successful remediation outcome need not produce flawless execution to create value. It only needs management to preserve supply continuity, hold its FY26 growth range, and prevent the recent margin damage from becoming structural. Ipratropium is the tangible proof point: the April launch delivered $8.4M in Q2 sales. Insulin aspart provides a second, later opportunity, with commercialization targeted for 2027 subject to regulatory approval.
The harder question is earnings quality. BAQSIMI demand is healthy at the prescription level, but price realization is deteriorating through rebates and 340B discounts. Glucagon is declining much faster than the rest of the company can tolerate if no new launches replace it. The $100M Lilly payment due after BAQSIMI crossed its annual-sales threshold also reduces financial flexibility at an inconvenient point in the remediation cycle. This is why the stock merits a buy rating, but not a high-conviction one.
A favorable outcome requires three things: IMS costs remain within guidance, launch revenue grows beyond the initial ipratropium contribution, and the company converts gross-margin improvement from higher-margin products into durable operating margin. If any one fails, the low TTM multiple may prove deserved. If all three hold, the current price does not reflect AMPH's forward earnings capacity.
Key Metrics
| Metric | Value | Context |
|---|---|---|
| Share price | $26.33 | Current price, 10.8% below the 52-week high of $29.52 |
| Market capitalization | $1.1B | Current equity value |
| Revenue | $0.7B FY2025 | 2.2% YoY growth |
| EPS | $2.10 FY2025 | 14.8% YoY decline |
| Operating margin | 15.7% LTM to 2026-06-30 | Below 26.7% FY2025 |
| Net margin | 10.8% LTM to 2026-06-30 | Below 19.4% FY2025 |
| P/E | 14.64x TTM | Versus peer average 40.0x |
| P/S | 1.52x TTM | Versus peer average 1.7x |
| Leverage | 3.60x debt/EBITDA LTM to 2026-06-30 | Total debt was $0.7B as of 2026-06-30 |
| Free cash flow | $0.2B LTM to 2026-06-30 | Cash-flow quality score is 100/100 |
| FY26 sales guidance | Mid-single digit to high-single digit growth | Reaffirmed on the 2026 Q2 call |
| Price momentum | +30.09% over 3 months | Price is 18.3% above its 200-day average |
Financial Strength
AMPH has adequate near-term liquidity, reflected in a 2.40 current ratio as of June 30, 2026, and meaningful LTM cash generation. The concern is not immediate solvency but flexibility: $0.7B of debt and 3.60x LTM debt/EBITDA leave less room for operational surprises, particularly alongside the $100M Lilly obligation. Margin direction is the central financial-health variable. Q2 showed sharp EBITDA recovery, but the much lower LTM operating and net margins show that the benefit has not yet translated into a stable trailing earnings base.
Competitive Position
AMPH's protection comes from difficult-to-replicate sterile, inhalation, and complex injectable manufacturing, plus FDA approvals and commercial relationships around products such as BAQSIMI and Primatene Mist. That moat is meaningful in technical products, but not absolute: glucagon's 42% YoY decline illustrates that product competition can overwhelm formulation advantages. Over three to five years, the moat improves only if the company converts its manufacturing base into reliable launches while restoring quality-system credibility at IMS.
Management & Guidance
Management reaffirmed FY26 net-sales growth of mid-single digit to high-single digit despite revising product-level assumptions, which signals confidence in portfolio breadth rather than a single franchise. The guidance is credible only within limits: ipratropium's $8.4M Q2 contribution supports it, but IMS remediation costs of $2M-$3M per quarter and modest batch-release delays make the path uneven. The near-term margin message is also measured, with management expecting the next quarter to resemble Q2 as higher BAQSIMI sales offset IMS costs. Given four beats and four misses over the last eight quarters, guidance should be treated as achievable but not bankable.
Segment Analysis
- IMS facility portfolio (Roughly one-third of sales): The facility remains operational, but added quality reviews are causing modest batch-release delays and $2M-$3M quarterly remediation expense.
- Ipratropium Bromide Inhalation ($8.4M of Q2 2026 revenue): Launched in April 2026 and led Q2 growth, providing early evidence that respiratory launches can add revenue.
- BAQSIMI (Exact revenue not disclosed): Prescriptions grew 17% YoY, but sales fell 3% YoY as rebates and 340B discounts reduced net price; annual sales exceeded $175M.
- Glucagon (Exact revenue not disclosed): Sales fell 42% YoY in Q2 as ready-to-use competitive products intensified pressure.
- Geography (Not disclosed in supplied current data): The prior European BAQSIMI transition had supply disruptions across 14 countries, but current geographic revenue is unavailable.
Capital Allocation
The company generated $0.2B of LTM FCF and used approximately $45M for Q2 repurchases, continuing the board's earlier $50M authorization. That capital return is attractive at a 14.64x TTM P/E, but leverage of 3.60x LTM debt/EBITDA argues for prioritizing debt capacity, the pending $100M Lilly payment, and remediation needs before aggressive buybacks. Supplied deep-dive data lists zero capex, dividends, and buybacks, so confirmed Q2 repurchases are the more reliable indicator of current deployment.
Management Execution & Track Record
Management's record is mixed rather than serially strong: the last eight reported quarters contain four beats and four misses, including a 46.8% Q2 2026 beat after misses of 40.0% and 19.2% in the prior two quarters. Since the 2024 Q3 call, EBITDA margin improved from 21.9% to 33.5% in Q2 2026, but Q2 gross margin was only 51% versus 53% two years earlier, and LTM operating margin is 15.7%. The 2024 promise of BAQSIMI peak sales of $250M-$275M has not been confirmed, while current sales cleared the $175M payment threshold but declined 3% YoY in Q2. Insulin aspart was discussed as a Q4 2024 BLA refiling, yet commercial launch is now expected in 2027 subject to approval; this is progress, not proof that the original timeline translated into revenue. Management deserves credit for retaining FY26 growth guidance through remediation, but the uneven beat record and unresolved facility work keep credibility below high-conviction levels.
Positioning & Flows
Institutional ownership is concentrated, with the top three institutions holding 55.4%, while insiders hold 9.0%. Short interest is elevated at 13.85% of shares, or 4.33M shares, with 9.2 days to cover on a 31M float, creating upside pressure if execution improves but also signaling material skepticism. Options gamma is reported as positive, but no usable zero-gamma or strike-wall levels were supplied, so it should not drive the investment decision.
Bull Case
- Q2 revenue rose 5% YoY to $183.9M, and management did not reduce its FY26 corporate sales-growth outlook despite the IMS work.
- Ipratropium generated $8.4M in its first full quarter after the April launch, showing that the respiratory pipeline can replace pressure on older products.
- BAQSIMI prescriptions increased 17% YoY, indicating underlying franchise demand even though Q2 reported BAQSIMI sales declined 3% YoY on net-price pressure.
- AMPH produced $0.2B of LTM FCF against a $1.1B market capitalization and repurchased about $45M of stock in Q2.
Bear Case
- IMS represents roughly one-third of sales and requires $2M-$3M of expense per quarter for the next several quarters, with added quality reviews already causing batch-release delays.
- LTM operating margin was 15.7% through June 30, 2026, down from 26.7% in FY2025, showing that the recovery seen in Q2 is not yet reflected in trailing profitability.
- Glucagon sales declined 42% YoY in Q2 amid intensifying competition, while BAQSIMI net sales declined 3% YoY despite prescription growth.
- Leverage is meaningful at 3.60x LTM debt/EBITDA and 0.90 debt/equity as of June 30, 2026, ahead of a $100M Lilly payment triggered by BAQSIMI crossing its $175M sales threshold.
Valuation & Price Target
Engine price target $38.52 (+46.3% vs current), Low confidence.
- P/E Multiple: $55.68 (22% weight)
- P/S Multiple: $23.98 (20% weight)
- Quality-adjusted: $28.89 (20% weight)
- DCF: $90.78 (2% weight)
The rating agrees with the quant BUY call but assigns Medium, not high, conviction. The engine's $38.52 target implies 46.3% upside from $26.33 and is supported by a low 14.64x TTM P/E, but its peer-multiple input is weak because the four-peer average is 40.0x with 4.2x dispersion and several peers are poor comparables. AMPH's actual fundamentals justify a discount until IMS costs, leverage at 3.60x LTM debt/EBITDA, and LTM margin compression are resolved. Sell-side consensus is low-signal, only four firms with 0 buy, 3 hold, and 1 sell, and does not outweigh the valuation or the company-specific operating evidence.
Risk Assessment
Risk score 53/100 (Moderate). The IMS remediation issue could turn from a $2M-$3M quarterly cost into a broader supply or regulatory disruption across roughly one-third of sales, impairing both FY26 growth and margin recovery.
The Bottom Line
AMPH rates a BUY with Medium conviction for the next 6-12 months. The valuation discounts real problems, but it also discounts the maintained FY26 growth outlook, new respiratory revenue, and a possible 2027 insulin aspart contribution. The November 5 earnings release is the immediate test of whether Q2 was a recovery or an isolated quarter. A downgrade would follow evidence that IMS disruption spreads beyond its current roughly one-third sales exposure, remediation costs exceed the guided range, or management cuts the FY26 growth outlook.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr